Format

Send to

Choose Destination
Eur J Cancer Prev. 2017 Sep;26 Joining forces for better cancer registration in Europe:S139-S146. doi: 10.1097/CEJ.0000000000000380.

Evaluation of completeness of case ascertainment in Swiss cancer registration.

Author information

1
aNational Institute for Cancer Epidemiology and Registration bEpidemiology, Biostatistics and Prevention Institute, University of Zurich cCancer Registry Zurich and Zug, University Hospital Zurich, Zurich dTicino Cancer Registry, Institute of Pathology, Locarno eGeneva Cancer Registry, Institute for Social and Preventive Medicine, Geneva University, Geneva fVaud Cancer Registry, University Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne gFribourg Cancer Registry, Fribourg hDepartment of Health and Social Affairs, Aargau, Aarau iCancer Registry St. Gallen-Appenzell, St. Gallen jCancer Registry Grison-Glarus, Chur kValais Cancer Registry, Health Observatory Valais, Sion lNeuch√Ętel and Jura Cancer Registry, Neuch√Ętel mCancer Registry Basel-Stadt and Basel-Land, Department of Public Health, Basel, Switzerland.

Abstract

This is the first comprehensive evaluation of completeness of case ascertainment in Swiss cancer registration. There is currently no method available that is considered to be the gold standard. Apart from simple measures such as the proportion of cases where registration was initiated by a death certificate and the proportion of diagnoses on the basis of histology or cytology/haematology, we applied two dedicated approaches: (i) the semiquantitative method of comparing the mortality to incidence rate ratio with relative survival (MI-Surv method) and (ii) the Flow method, which provides a quantitative estimate for the completeness depending on time since diagnosis. All 10 Swiss cancer registries in operation since at least 2006 and providing the required parameters were included. Simple and dedicated methods showed high completeness across all cancer registries and for most cancer types tested, with the notable exception of lymphoid leukaemia.

PMID:
28574868
DOI:
10.1097/CEJ.0000000000000380
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for Zurich Open Access Repository and Archive
Loading ...
Support Center